Earnings ·
Ardelyx, Inc. reported second quarter 2026 financial results with total product revenue of $118.1 million, a 31%…
ARDXArdelyx, Inc.
Ardelyx, Inc. reported second quarter 2026 financial results with total product revenue of $118.1 million, a 31% year-over-year increase driven by IBSRELA ($86.2 million) and XPHOZAH ($31.9 million). The company revised its full-year 2026 IBSRELA revenue guidance down to $350–$370 million due to increased payor utilization management, while reiterating XPHOZAH guidance of $110–$120 million and lowering operating expense guidance below $500 million. Ardelyx reported a net loss of $16.7 million ($0.07 per share) and holds $281.8 million in cash, cash equivalents, and investments as of June 30, 2026. Additionally, the company drew $50 million from its financing arrangement with SLR Investment Corp. on June 29, 2026, and concluded litigation against CMS regarding XPHOZAH reimbursement classification. Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs.